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a  b  s  t  r  a  c  t
Hematopoietic stem cell transplantation is the curative option for patients with myelodys-
plastic syndrome; however, it requires a long post-transplantation follow-up. A 53-year-old
woman with a diagnosis of myelodysplastic syndrome underwent related donor allogeneic
hematopoietic stem cell transplantation in July 2006. Three months after transplanta-
tion,  a comparative short tandem repeat analysis between donor and recipient revealed
full  chimerism, indicating complete, healthy bone marrow reconstitution. Three years
and  ten months after hematopoietic stem cell transplantation, the patient developed
leukopenia and thrombocytopenia. Another short tandem repeat analysis was carried out
which showed mixed chimerism (52.62%), indicating relapsed disease. A donor lymphocyte
infusion was administered. The purpose of donor lymphocyte infusion is to induce a graft-
versus-leukemia effect; in fact, this donor’s lymphocyte infusion induced full chimerism.
Successive short tandem repeat analyses were performed as part of post-transplantation
follow-up, and in July 2010, one such analysis again showed mixed chimerism (64.25%).
Based  on this ﬁnding, a second donor lymphocyte infusion was administered, but failed
to  eradicate the disease. In September 2011, the patient presented with relapsed dis-
ease,  and a second related donor allogeneic hematopoietic stem cell transplantation
was  performed. Subsequent short tandem repeat analyses revealed full chimerism, indi-
cating complete bone marrow reconstitution. We  conclude that quantitative detection
of  mixed chimerism is an important diagnostic tool that can guide early therapeutic
intervention.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is an effective
treatment for patients with immunological and hemato-
logic diseases, including myelodysplastic syndrome (MDS).1
In HSCT, the donor cells restore the recipient bone mar-
row, producing new blood cells that are responsible for
the hematopoietic and immunological reconstitution of the
recipient. Consequently, HSCT results in a restoration of
hematopoiesis and in a gradual change of hematopoietic
cell genetics from the recipient proﬁle to the donor proﬁle.
This change of genetic proﬁle, in which donor and recipient
hematopoietic cells can coexist, is called chimerism.2
One of the methods used to verify chimerism is short
tandem repeat (STR) testing. STRs, or microsatellites, are
repetitive sequences of three to seven base pairs that iden-
tify different alleles by the number of copies of repetitive
sequences contained in the DNA region analyzed. STRs exhibit
a high level of heterozygosity, high polymorphism and are
highly informative of human individuality.3
The study of STRs uses the polymerase chain reaction (PCR)
technique, which enables the selective ampliﬁcation of spe-
ciﬁc DNA sequences. The advantages of PCR include the small
number of cells required for analysis and the technique’s high
sensitivity, as it is able to detect 1 cell in 1 × 106.3
Thus, the role of STRs as markers of chimerism status after
HSCT has been used to guide clinical interventions to achieve
success in HSCT.4
Case  report
On 10 November 2004, a 53-year-old woman was diagnosed
with MDS  with an International Prognostic Scoring System
(IPSS) stage of Intermediate 2. Her karyotype at diagnosis fea-
tured deletions of chromosomes 1 and 6. The patient was
referred for related donor HSCT (identical HLA sibling – Donor
#1) as a therapeutic option due to the high risk of transfor-
mation to acute myeloid leukemia (AML). Prior to HSCT, an
analysis of the STR proﬁles of 15 loci and the amelogenin
locus was conducted in donor and recipient blood samples
to enable follow-up of the changes in genetic proﬁle in recip-
ient hematopoietic cells which would signal reconstitution of
hematopoiesis and engraftment. STR analysis was performed
by multiplex PCR and the detection of the PCR products was
performed in an ABI 3100 Avant Genetic Analyzer with the
Identiﬁler kit (Applied Biosystems®).4
The pre-transplantation conditioning regimen consisted of
busulfan and cyclophosphamide, with the HSCT being per-
formed in July 2006 with 2.4 × 106 CD34+ cells/kg. The patient
did not develop acute graft-versus-host disease (GVHD).
Engraftment occurred at Day +26 as evaluated by blood count
and bone marrow aspiration. Three months after the HSCT,
a follow-up STR analysis revealed full chimerism; in other
words, the genetic proﬁle in the recipient’s blood sample was
identical to the donor proﬁle, indicating full engraftment with-
out molecular evidence of disease recurrence.
In April 2010, three years and ten months after the HSCT,
the patient developed leukopenia and thrombocytopenia. 2 0 1 4;3  6(5):369–372
Another STR analysis was performed which showed mixed
chimerism (donor and receptor cells coexisting), indicating
relapse of the disease. Chimerism was quantiﬁed using the
area under the curve peaks of the electropherogram as per
Kristt et al.4 using ﬁve informative loci of STRs and the result
was 52.62% donor chimerism.
To halt disease progression, a donor lymphocyte infu-
sion (DLI) was performed with the objective of inducing a
graft-versus-leukemia (GVL) reaction. The patient received
1 × 107 CD3+ cells/kg. Two months after the infusion, in June
2010, the patient again presented full chimerism, indicating
that the DLI was effective.
A further follow-up was performed by blood counts and
bone marrow aspiration. The patient remained clinically sta-
ble and without clinical or hematological evidence of relapse
until July 2010, when STR analysis showed 64.25% donor
chimerism. Based on these results, a second DLI  was per-
formed in an attempt to induce an early GVL response and
prevent a major recurrence. STR analysis performed after this
DLI, in September 2010, revealed 51.20% donor chimerism,
indicating the persistence of this phenomenon. Although
mixed chimerism persisted, the patient remained clinically
stable and the therapeutic options were evaluated.
In August 2011, the patient developed pancytopenia. As
she had another HLA-identical sibling (Donor #2), a second
HSCT was performed on 23 September 2011. The conditioning
regimen consisted of busulfan and melphalan, and the HSCT
was performed with an infusion of 1.6 × 106 CD34+ cells/kg.
Engraftment occurred at Day +19 as evaluated by blood counts
and bone marrow aspiration. The patient was tested for
chimerism in October 2011, January 2012, September 2012 and
September 2013. All investigations revealed full chimerism,
indicating complete bone marrow recovery. Results are sum-
marized in Table 1.
Discussion
One of the most widely used parameters for monitoring in the
post-HSCT period is the donor:recipient DNA ratio. This con-
dition is estimated and expressed as the percentage of donor
chimerism. A value approaching 100% indicates a greater
number of donor cells in the analyzed sample. After HSCT, the
optimal goal is 100% donor chimerism. When this condition is
achieved, it is known as ‘full chimerism’.4
Informative loci were used for calculation purposes, which
was performed by measuring the area under the curve
of the peaks on an electropherogram. The formula was
(D1 + D2/D1 + D2 + R1 + R2) × 100, where D1, D2, R1 and R2 rep-
resent the area under the curve of recipient and donor alleles.4
After the ﬁrst HSCT, the FGA, TH01, D2S1338, D7S820 and
D18S51 loci were used to calculate mixed chimerism, because
they were informative loci. The calculated coefﬁcient of vari-
ation was <10%. These results are consistent with the Kristt
et al. acceptance criteria.5
It is well known that the success of HSCT depends, in part,
on the GVL effect induced by the donor T lymphocytes. The
GVL effect plays an important role in disease eradication in
patients with hematologic malignancy treated by HSCT.1 In
our patient, the purpose of administering a DLI was to initiate
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Table 1 – Results of short tandem repeat analysis in samples of recipient and donor peripheral blood.
Locus Recipient
alleles before
HSCT
Donor #1
alleles
Recipient
alleles after
ﬁrst HSCT
10/2006
Recipient
alleles after
ﬁrst HSCT
4/2010
Recipient
alleles after
ﬁrst HSCT
6/2010
Recipient
alleles after
ﬁrst HSCT
7/2010
Recipient
alleles after
ﬁrst HSCT
9/2010
Donor #2
alleles
Recipient
alleles after
second
HSCT
16/09/2013
AMELO X,X X,Y X,Y X,Y X,Y X,Y X,Y X,Y X,Y
D5S818 11,13 11,13 11,13 11,13 11,13 11,13 11,13 NT NT
FGA 19,24 19,23 19,23 19,23,24 19,23 19,23,24 19,23,24 21,23 21,23
D19S433 13,14 13,– 13,– 13,14 13,– 13,14 13,14 NT NT
vWA 17,18 17,– 17,– 17,18 17,– 17,18 17,18 14,18 14,18
TPOX 8,9 8,9 8,9 8,9 8,9 8,9 8,9 8,11 8,11
D18S51 16,18 13,14 13,14 13,14,16,18 13,14 13,14,16,18 13,14,16,18 16,18 16,18
D3S1358 15,16 15,16 15,16 15,16 15,16 15,16 15,16 15,16 15,16
TH01 8,9.3 7,9.3 7,9.3 7,8,9.3 7,9.3 7,8,9.3 7,8,9.3 8,9.3 8,9.3
D13S317 11,12 11,12 11,12 11,12 11,12 11,12 11,12 11,12 11,12
D16S539 12,– 12,13 12,13 12,13 12,13 12,13 12,13 12,– 12,–
D2S1338 20,23 19,25 19,25 19,20,23,25 19,25 19,20,23,25 19,20,23,25 NT NT
D8S1179 13,14 13,– 13,– 13,14 13,– 13,14 13,14 13 13
D21S11 28,30 28,30 28,30 28,30 28,30 28,30 28,30 NT NT
D7S820 8,10 8,9 8,9 8,9,10 8,9 8,9,10 8,9,10 9,– 9,–
CSF1PO 10,11 10,13 10,13 10,13 10,13 10,13 10,13 10,13 10,13
% Donor
chimerism
–  – Full
chimerism
52.62 Full
chimerism
64.25 51.20 – Full
chimerism
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3HSCT: hematopoietic stem cell transplantation; NT: not tested.
 GVL response capable of inhibiting the dysplastic clones
hat had resisted the conditioning and follow-up regimens.
dministering a DLI on the basis of blood counts, bone mar-
ow aspiration, and karyotype ﬁndings alone could expose
he patient to an unnecessary risk of GVHD. Mixed chimerism
uantiﬁcation enables correct treatment decisions, such as
erforming DLIs only when adequate and necessary. Admin-
stration of a DLI to patients with donor chimerism ≥40% is
trongly associated with conversion to full chimerism. In this
ase, the beneﬁt of the DLI would be signiﬁcantly superior to
he risk of developing GVHD.6 Therefore, the importance of
ixed chimerism quantiﬁcation as a tool to support adequate,
orrect, and early treatment decisions cannot be overstated.
The second DLI administered to our patient failed to induce
ull chimerism, which suggests that this DLI was unable to
chieve maximum antitumor effect and thus eradicate the dis-
ase. Campregher et al. found that patients with MDS  with
igh-risk IPSS stages treated with DLI have better results
han patients with intermediate IPSS. These authors found
hat the major response to the DLI observed in patients
ith MDS  and high-risk IPSS is due to the high expression
f tumor-associated antigens in these patients. This high
ntigen expression may make the neoplastic clone more  sus-
eptible to immune attack by the DLI.7
In the present case, administration of DLIs to a patient with
PSS Intermediate-2 MDS  did not seem to produce a long-term
esult, but these DLIs were able to induce complete remis-
ion, with low risk of mortality at times when few therapeutic
ptions were available. The quantiﬁcation of mixed chimerism
ontributed to the decision to perform a second HSCT using
nother sibling as donor. At the time of writing, the patient
as clinically stable, transfusion-independent, and without
ny clinical complications.
4In this case, STR analysis through multiplex PCR followed
by detection in a genetic analyzer allowed early clinical inter-
vention and contributed decisively to post-transplantation
therapy. Mixed chimerism quantiﬁcation was of fundamen-
tal importance to support decisions about DLI  administration.
In conclusion, quantitative follow-up of the chimerism pro-
ﬁle after HSCT is a valuable diagnostic tool that enables early
intervention in the post-transplantation period.
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